超声引导下经皮射频消融联合^(125)I放射性粒子植入术治疗肝癌的疗效分析  

Efficacy of ultrasound-guided percutaneous radiofrequency ablation combined with ^(125)I radioactive seed implantation in the treatment of liver cancer

作　　者：卢斌 董科 翁文超 张兆辉 王升晔 LU Bin;DONG Ke;WENG Wenchao;ZHANG Zhaohui;WANG Shengye(Department of Ultrasonography,Affiliated Jinhua Hospital Zhejiang University School of Medicine,Jinhua 321000,China;不详)

机构地区：[1]浙江大学医学院附属金华医院超声医学科,321000 [2]浙江大学医学院附属金华医院核医学科 [3]浙江大学医学院附属金华医院肝胆胰外科 [4]中国科学院大学附属肿瘤医院(浙江省肿瘤医院)放疗科

出　　处：《浙江医学》2022年第16期1710-1713,1730,共5页Zhejiang Medical Journal

基　　金：金华市科学技术研究计划项目(2020-4-001)。

摘　　要：目的探讨超声引导下经皮射频消融术(RFA)联合^(125)I放射性粒子植入术治疗肝癌的疗效。方法选取2015年7月至2018年6月浙江大学医学院附属金华医院接受超声引导下RFA治疗的40例肝癌患者(对照组)与接受超声引导下RFA联合^(125)I放射性粒子植入术治疗的40例肝癌患者(观察组)。对两组患者的临床资料进行回顾,比较两组患者的疾病控制率、癌因性疼痛评分、癌因性疲乏评分,随访1、3年的存活率、肿瘤复发率,并比较两组存活患者的生存质量评分。结果观察组的疾病控制率为85.0%,高于对照组的65.0%(P<0.05)。与治疗前比较,两组患者治疗后的癌因性疼痛评分、癌因性疲乏评分均降低(均P<0.01);治疗后,观察组癌因性疼痛评分、癌因性疲乏评分均低于对照组(均P<0.01)。观察组1、3年存活率均高于对照组(均P<0.05),观察组1、3年肿瘤复发率均低于对照组(均P<0.05)。随访1、3年时,观察组存活患者的生存质量评分均高于对照组(均P<0.01)。结论超声引导下RFA联合^(125)I放射性粒子植入术可控制肝癌患者的肿瘤进展,减轻患者癌因性症状,从而提高患者的近中期存活率和生存质量,减少局部复发。Objective To explore the efficacy of ultrasound-guided percutaneous radiofrequency ablation combined with ^(125)I radioactive seed implantation in the treatment of liver cancer. Methods From July 2015 to June 2018, 40 patients with liver cancer who received ultrasound-guided percutaneous radiofrequency ablation(control group) and 40 liver cancer patients who received ultrasound-guided percutaneous radiofrequency ablation plus ^(125)I radioactive seed implantation(study group) in Affiliated Jinhua Hospital Zhejiang University School of Medicine were enrolled in the study. The disease control rate, cancer-related pain score, cancer-related fatigue score, 1-year and 3-year survival rate and 1-year and 3-year recurrence rate and the quality of life scores of the two groups were compared. Results The disease control rate of study group was higher than that of control group(85.0% vs. 65.0%, P<0.05). The scores of cancer-related pain and cancerrelated fatigue were decreased after treatment in both groups(P<0.01);while these indicators in study group were even lower than those in the control group(P<0.01). The 1-year and 3-year survival rates of the study group were significantly higher than those of the control group(P<0.05), while the 1-year and 3-year recurrence rates of the study group were significantly lower than those of the control group(P<0.01). After 1-year and 3-years of follow-up, the quality of life scores of the surviving patients in the study group were higher than those in the control group(P<0.01). Conclusion Ultrasoundguided percutaneous radiofrequency ablation combined with ^(125)I radioactive seed implantation may control the tumor progression, alleviate cancer-related symptoms, increase the survival rate, reduce local recurrence and improve the quality for liver cancer patients.

关 键 词：肝癌 超声引导 射频消融 ^(125)I放射性粒子植入术 

分 类 号：R735.7[医药卫生—肿瘤]